Wednesday, June 12, 2024

GMP/Manufacturing
Reimbursement Policy
Prescription and Non-Prescription Medicine Regulation
Prescription Medicine Regulation
Medical Devices Regulation
Medical Operations
Leadership, Wellness and Resilience
8:45 AM - 9:30 AM A01a. Fuelling Advancements in DIPG Research and Treatment: The Journey of a Scientist-Parent
9:30 AM - 10:30 AM A01b. The future of approval and access: The confluence of consumer collaborations and leadership competencies
10:30 AM - 11:15 AM Morning Tea (12 June)
11:15 AM - 12:15 PM A02. Update from the Manufacturing Quality Branch A03. Convergence of technologies – drug, device, diagnostics – policy implications A04. TGO 91 compliance workshop A05. Getting the most out of repurposing medicines A06. QMSR (Quality Management Regulatory System) , ISO 13485, 14971 and EU MDR comparison A07. Navigating the Dynamic Landscape of Medical Information: Embracing AI and Enhancing Patient-centricity A08. Burnout and Building Resilience" -What's all the fuss? Management,Prevention and Recovery
12:15 PM - 1:30 PM Lunch (12 June)
1:30 PM - 2:30 PM A09. GDP and GWP – what’s the difference? A10. Emergence of digital health – potential for healthcare and access challenges A11. TGO 92 compliance workshop A12. Medsafe updates A13. AI/ML in Medical Devices – Demystifying Global Requirements for premarket applications A14. Medical Affairs capability building – unlocking the network of the future A15. 5 Simple Strategies for Success
2:30 PM - 2:45 PM
Session change (12 June)
2:45 PM - 3:45 PM A16. Fundamentals of Digital Transformation A17. HTA review progress and where to from here? A18. Rare disease therapies: strategies and considerations in developing an orphan medicine A19. Crossing the Tasman: Insights into navigating the NZ regulatory terrain A20. Regulatory update from the Medical Devices Authorisations Branch (TGA) A21. The Rise of Patient Involvement and Value in the Evidence Lifecycle A22. Leading Change Intentionally
3:45 PM - 4:30 PM Afternoon Tea (12 June)
4:30 PM - 5:30 PM A23. Recent developments in ICH Q series guidances and Quality Manturity A24. Patient centricity in HTA – towards greater transparency and accountability A25. Update from the Complementary and Over the Counter Medicines Branch at TGA A26. Vaping Reforms and Implementation A27. Impact of the European Medical Device Directive to Medical Device Regulations transition on the Australian regulatory landscape A28. From Review to Reality: How Feedback is Shaping the Medicines Australia Code 19 Review A29. Creative Communication: Leveraging Individual Attributes for Effective Collaboration
5:30 PM - 6:30 PM Welcome Reception












Thursday, June 13, 2024

Clinical Research Landscape
Clinical Research
Prescription Medicines and Devices Regulation
Prescription Medicines Regulation
Reimbursement
Data, Technology and Informatics
Pharmacovigilance
8:45 AM - 10:30 AM B01. Pandora's black box - ethical and legal implications of AI in healthcare
10:30 AM - 11:15 AM Morning Tea (13 June)
10:40 AM - 11:10 AM D04. ARCS Competency Framework Q & A Session
11:15 AM - 12:15 PM B02. Update on Establishing the National One Stop Shop for Clinical Trials B03. The Privacy Act in Australia: A summary of your obligations and reporting requirements B04. Regulatory update from the Medical Devices Surveillance Branch B05. Navigating the Future: Regulatory insights and innovations in advanced therapeutics B06. The ABC's of R&R (Spoiler alert: we are talking Regulatory and reimbursement in the U.S. market, not rest and relaxation) B07. Revolutionising pharmaceutical regulatory efficiency: Harnessing the power of AI and LLM B08. RMP and RMMs - it takes a village
12:15 PM - 1:30 PM Lunch (13 June)
12:45 PM - 1:15 PM D05. Simplifying Safety Letter Distribution through Technology
Sponsored by Veeva Australia
1:30 PM - 2:30 PM B09. TGA Clinical Trial Landscape Updates B10. The CT:IQ InFORMed Project: Update on Implementing a redesigned Participant Information and Consent Form B11. Global Market Strategies: Utilising International Evidence and Navigating Regional Regulations for Medical Devices B12. Challenges of regulatory and logistics for bringing cell therapies to Australia B13. Navigating the Australian Medical Technologies Reimbursement and Funding Landscape B14. Transformative Technologies: Risk-Based AI Frameworks and Agile Intelligence in Healthcare Data B15. Update from the TGA Pharmacovigilance Branch
2:30 PM - 2:45 PM
Session change (13 June)
2:45 PM - 3:45 PM B16. NSW Health and Queensland Health sector updates B17. Complex Clinical Trials. Design, participation, conduct and HREC review - Part II B18. Prescription Medicine Authorisation Branch annual update B19. CMC variations: Navigating the greyzones B20. Sector readiness/preparedness for delivering cell and gene therapies - why aren't we there? B21. Coalition of the willing - change management in solution implementation B22. Unapproved medicines and PV (Clinical and SAS)
3:45 PM - 4:30 PM Afternoon Tea (13 June)
4:30 PM - 5:30 PM B23. Clinical trial sites perspectives on common challenges and practical solutions B24. Flexible approach to OGTR licences issued for the delivery of Gene therapy: one licence, multiple therapies B25. How to make sense of RNA-based therapeutics B26. Nitrosamine Impurities in Medicine - A Hot Topic B27. Horizon scanning - learnings from the past and defining a purpose and pathway for the future B28. What have we learnt and what to expect? B29. AI in PV
5:30 PM - 6:30 PM Networking Function
6:30 PM - 10:00 PM
Conference dinner and Vivid cruise experience



Pharmacovigilance
8:45 AM - 10:30 AM B01. Pandora's black box - ethical and legal implications of AI in healthcare
10:30 AM - 11:15 AM Morning Tea (13 June)
10:40 AM - 11:10 AM D04. ARCS Competency Framework Q & A Session
11:15 AM - 12:15 PM B08. RMP and RMMs - it takes a village
12:15 PM - 1:30 PM Lunch (13 June)
12:45 PM - 1:15 PM D05. Simplifying Safety Letter Distribution through Technology
Sponsored by Veeva Australia
1:30 PM - 2:30 PM B15. Update from the TGA Pharmacovigilance Branch
2:30 PM - 2:45 PM
Session change (13 June)
2:45 PM - 3:45 PM B22. Unapproved medicines and PV (Clinical and SAS)
3:45 PM - 4:30 PM Afternoon Tea (13 June)
4:30 PM - 5:30 PM B29. AI in PV
5:30 PM - 6:30 PM Networking Function
6:30 PM - 10:00 PM
Conference dinner and Vivid cruise experience







Pharmacovigilance
8:45 AM - 10:30 AM B01. Pandora's black box - ethical and legal implications of AI in healthcare
10:30 AM - 11:15 AM Morning Tea (13 June)
10:40 AM - 11:10 AM D04. ARCS Competency Framework Q & A Session
11:15 AM - 12:15 PM B08. RMP and RMMs - it takes a village
12:15 PM - 1:30 PM Lunch (13 June)
12:45 PM - 1:15 PM D05. Simplifying Safety Letter Distribution through Technology
Sponsored by Veeva Australia
1:30 PM - 2:30 PM B15. Update from the TGA Pharmacovigilance Branch
2:30 PM - 2:45 PM
Session change (13 June)
2:45 PM - 3:45 PM B22. Unapproved medicines and PV (Clinical and SAS)
3:45 PM - 4:30 PM Afternoon Tea (13 June)
4:30 PM - 5:30 PM B29. AI in PV
5:30 PM - 6:30 PM Networking Function
6:30 PM - 10:00 PM
Conference dinner and Vivid cruise experience


Friday, June 14, 2024

Clinical Research
Diversity, Inclusiveness and Consumer Engagement
Clinical Workforce and Capacity
BioBeacon
Innovation/General Interest
Leadership, Wellness and Resilience
Careers and the MTP Sector
8:45 AM - 9:30 AM C01a. From Discovery to FDA Approval: The 30-Year Odyssey, an Australian Biomedical Triumph
9:30 AM - 10:30 AM C01b. Gene and Cell Therapy: Leading change through translation pathways
10:30 AM - 11:15 AM Morning Tea (14 June)
11:15 AM - 12:15 PM C02. How to promote confidence in clinical trials, and undo misinformation, in your social circles & communities C03. A site and sponsor -facing Caregiver Advisory Board: a forward-thinking approach to early protocol development and feasibility C04. Unlocking Potential: Exploring the Clinical Trials Workforce and Research Grant Impact BB01. BioBeacon: ARIA Research, Roam Technologies and dermRhealth C06. Gene and Cell Therapy: Running efficient Clinical Trials with Multi-Disciplinary teams C07. The Secrets of Maximising Your Potential S1. Careers in the MTP sector - Overview of the sector and stakeholder
12:15 PM - 1:30 PM Lunch (14 June)
12:45 PM - 1:15 PM D08. On the frontline of Ramsay Research: Learnings from the Clinical Trials Sites
Sponsored by Ramsay Research
1:30 PM - 2:30 PM C09. Safety Reporting and Clinical Incidents - What to Report and Why C10. Diversity in clinical research C11. Building Strong Clinical Trial Teams: Enhancing Efficiency and Cohesion BB02. BioBeacon: Zymedyne Therapeutics, Culturon and Ab Initio Pharma C13. Capacity building on early phase challenge trials (infectious diseases case study – malaria research) C14. Elevate Your Leadership: Unlock Your "Leadership Why" To Propel Your Influence & Impact S2. Careers in the MTP sector - Spotlight on the clinical research landscape
2:30 PM - 2:45 PM
Session change (14 June)
2:45 PM - 3:45 PM C16. Innovations in recruiting participants C17. What patients and their families need from clinical trials C18. Stories from the Summit: Harnessing the National Clinical Trials Governance Framework to deliver Health Service Safety, Quality, Culture, Capacity to the Community BB03. BioBeacon: iiShield, Eudaemon Technologies and NGB Innovation C20. Revolutionizing Clinical Trials: Innovation in approval processes and trial design C21. Creating a Compelling Ambition S3. Careers in the MTP sector - Spotlight on regulatory and pharmacovigilance
3:45 PM - 4:30 PM Afternoon Tea (14 June)
4:30 PM - 5:30 PM C23. Meeting the National Clinical Trials Governance Framework's expectations for patient engagement and partnering C24. Community Involvement in Clinical Trials C25. Australian Teletrial Program (ATP) - Sector updates C27. Being inspection ready in a digital clinical trial space C28. Building Flow into Your Work S4. Careers in the MTP sector - Medical Affairs, MI and Reimbursement
5:30 PM - 6:30 PM Closing Reception












loading